Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.

Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Psaromyalou A, Angelopoulou A, Kalofonos HP.

Cancer. 2013 Oct 1;119(19):3570-7. doi: 10.1002/cncr.28234. Epub 2013 Jul 2.

2.

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.

Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, Cacciavillani M, Lonardi S, Santos C, Cortinovis D, Cazzaniga M, Kalofonos HP.

Ann Oncol. 2012 Dec;23(12):3116-22. doi: 10.1093/annonc/mds208. Epub 2012 Aug 2.

PMID:
22865779
3.

Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.

Briani C, Argyriou AA, Izquierdo C, Velasco R, Campagnolo M, Alberti P, Frigeni B, Cacciavillani M, Bergamo F, Cortinovis D, Cazzaniga M, Bruna J, Cavaletti G, Kalofonos HP.

J Peripher Nerv Syst. 2014 Dec;19(4):299-306. doi: 10.1111/jns.12097.

PMID:
25582667
4.

Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.

Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP, Canonico PL, Genazzani AA, Cavaletti G.

J Peripher Nerv Syst. 2015 Mar;20(1):15-23. doi: 10.1111/jns.12110.

PMID:
25858589
5.

Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.

Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP.

Cancer. 2013 Jan 15;119(2):438-44. doi: 10.1002/cncr.27732. Epub 2012 Jul 11.

6.

Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.

Lucchetta M, Lonardi S, Bergamo F, Alberti P, Velasco R, Argyriou AA, Briani C, Bruna J, Cazzaniga M, Cortinovis D, Cavaletti G, Kalofonos HP.

Cancer Chemother Pharmacol. 2012 Dec;70(6):899-902. doi: 10.1007/s00280-012-2006-8. Epub 2012 Oct 30.

PMID:
23108696
7.

Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.

Tsuruta A, Yamashita K, Tanioka H, Tsuji A, Inukai M, Yamakawa T, Yamatsuji T, Yoshimitsu M, Toyota K, Yamano T, Nagasaka T, Okajima M.

Drug Des Devel Ther. 2016 Nov 23;10:3827-3835. eCollection 2016.

8.

The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.

Chen XF, Wang R, Yin YM, Røe OD, Li J, Zhu LJ, Guo RH, Wu T, Shu YQ.

Biomed Pharmacother. 2012 Jun;66(4):279-84. doi: 10.1016/j.biopha.2012.01.002. Epub 2012 Feb 17.

PMID:
22397758
9.

Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.

Argyriou AA, Briani C, Cavaletti G, Bruna J, Alberti P, Velasco R, Lonardi S, Cortinovis D, Cazzaniga M, Campagnolo M, Santos C, Kalofonos HP.

Eur J Neurol. 2013 May;20(5):788-94. doi: 10.1111/ene.12061. Epub 2012 Dec 17.

PMID:
23252594
10.

Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.

Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, Frigeni B, Cacciavillani M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP.

J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):392-8. doi: 10.1136/jnnp-2013-305334. Epub 2013 Jun 29.

PMID:
23813745
11.

FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.

Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, Roviello F, Nettuno R, Intrivici C, Tanzini G, Lorenzi M, Francini G.

Oncology. 2006;70(5):345-50. Epub 2006 Dec 15.

PMID:
17179728
12.

Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.

Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ.

Eur J Cancer. 2009 Mar;45(4):572-8. doi: 10.1016/j.ejca.2008.10.015. Epub 2008 Dec 10.

PMID:
19084393
13.

A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.

Beijers AJ, Mols F, Vreugdenhil G.

Support Care Cancer. 2014 Jul;22(7):1999-2007. doi: 10.1007/s00520-014-2242-z. Epub 2014 Apr 13. Review.

PMID:
24728618
14.

Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.

Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G.

Support Care Cancer. 2013 May;21(5):1313-9. doi: 10.1007/s00520-012-1667-5. Epub 2012 Nov 30. Erratum in: Support Care Cancer. 2013 Apr;21(4):1209. Silvestris, Nicola [added].

PMID:
23196819
15.

Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.

Chay WY, Tan SH, Lo YL, Ong SY, Ng HC, Gao F, Koo WH, Choo SP.

Asia Pac J Clin Oncol. 2010 Dec;6(4):270-7. doi: 10.1111/j.1743-7563.2010.01344.x.

PMID:
21114776
16.

Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?

Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R.

Support Care Cancer. 2010 Oct;18(10):1263-70. doi: 10.1007/s00520-009-0740-1. Epub 2009 Sep 12.

PMID:
19756772
17.

[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].

Muto O, Ando H, Ono T, Itagaki H, Kobayashi Y, Onuki M, Akashi T, Tanaka Y, Hanaoka T.

Gan To Kagaku Ryoho. 2007 Apr;34(4):579-81. Japanese.

PMID:
17431344
18.

[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].

Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C.

Dtsch Med Wochenschr. 2002 Jan 18;127(3):78-82. German.

PMID:
11797144
19.

The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.

Knijn N, Tol J, Koopman M, Werter MJ, Imholz AL, Valster FA, Mol L, Vincent AD, Teerenstra S, Punt CJ.

Eur J Cancer. 2011 Feb;47(3):369-74. doi: 10.1016/j.ejca.2010.10.006. Epub 2010 Nov 8.

PMID:
21067912
20.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L.

J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898.

PMID:
18421053

Supplemental Content

Support Center